Skip to main content
Erschienen in: World Journal of Surgery 6/2012

01.06.2012

Long-Term Results of Surgery for Small Intestinal Neuroendocrine Tumors at a Tertiary Referral Center

verfasst von: Olov Norlén, Peter Stålberg, Kjell Öberg, John Eriksson, Jakob Hedberg, Ola Hessman, Eva Tiensuu Janson, Per Hellman, Göran Åkerström

Erschienen in: World Journal of Surgery | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Small intestinal neuroendocrine tumors (SI-NETs) are uncommon, with an annual incidence of about 1 per 100,000 individuals. The primary tumor (PT) is generally small, but nevertheless the majority of patients have mesenteric lymph node metastases and liver metastases at diagnosis. Our aim was to identify prognostic factors for survival and to evaluate outcome after surgery in SI-NET patients.

Material and Methods

We included 603 consecutive patients (325 men; age at diagnosis 63 ± 11 years [mean ± SD]) with histopathologically verified SI-NET, who were diagnosed between 1985 and 2010. Hospital charts were reviewed and were scrutinized for carcinoid heart disease (CHD), flush and/or diarrhea, proliferation by Ki-67 index, mesenteric lymph node metastases (m.lgllm), distant abdominal lymph node metastases (da.lgllm), liver tumor load (LTL), extra-abdominal metastases (EAM), locoregional resective surgery, as well as debulking of LTL, and adverse events after surgery.

Results

Median overall survival (OS) was 8.4 years; 5-year OS was 67%, and 5-year relative survival was 74%. Independent prognostic factors by univariate and multivariate analysis were age at diagnosis, CHD, m.lgllm, da.lgllm, LTL, EAM, peritoneal carcinomatosis (PC), and proliferation. Locoregional resective surgery was associated with increased survival on crude and multivariate analysis. The 30-day mortality in our institution after initial locoregional resective surgery was 0.5% (1/205).

Conclusions

For the first time, m.lgllm and da.lgllm, LTL, PC, and EAM are demonstrated to be independent prognostic factors by multivariate analysis. Locoregional removal of the PT/m.lgllm. was a positive prognostic factor by crude and adjusted analysis and may influence survival.
Literatur
1.
Zurück zum Zitat Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072PubMedCrossRef Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072PubMedCrossRef
2.
Zurück zum Zitat Zar N, Garmo H, Holmberg L et al (2004) Long-term survival of patients with small intestinal carcinoid tumors. World J Surg 28:1163–1168PubMedCrossRef Zar N, Garmo H, Holmberg L et al (2004) Long-term survival of patients with small intestinal carcinoid tumors. World J Surg 28:1163–1168PubMedCrossRef
3.
Zurück zum Zitat Makridis C, Oberg K, Juhlin C et al (1990) Surgical treatment of mid-gut carcinoid tumors. World J Surg 14:377–383 discussion 384–375PubMedCrossRef Makridis C, Oberg K, Juhlin C et al (1990) Surgical treatment of mid-gut carcinoid tumors. World J Surg 14:377–383 discussion 384–375PubMedCrossRef
4.
Zurück zum Zitat Åkerstrom G, Hellman P, Hessman O (2005) Midgut carcinoid tumours: surgical treatment and prognosis. Best Pract Res Clin Gastroenterol 19:717–728CrossRef Åkerstrom G, Hellman P, Hessman O (2005) Midgut carcinoid tumours: surgical treatment and prognosis. Best Pract Res Clin Gastroenterol 19:717–728CrossRef
5.
Zurück zum Zitat Pape UF, Jann H, Muller-Nordhorn J et al (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113:256–265PubMedCrossRef Pape UF, Jann H, Muller-Nordhorn J et al (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113:256–265PubMedCrossRef
6.
Zurück zum Zitat Janson ET, Holmberg L, Stridsberg M et al (1997) Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8:685–690PubMedCrossRef Janson ET, Holmberg L, Stridsberg M et al (1997) Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8:685–690PubMedCrossRef
7.
Zurück zum Zitat Moller JE, Pellikka PA, Bernheim AM et al (2005) Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation 112:3320–3327PubMedCrossRef Moller JE, Pellikka PA, Bernheim AM et al (2005) Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation 112:3320–3327PubMedCrossRef
8.
Zurück zum Zitat Strosberg J, Gardner N, Kvols L (2009) Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 89:471–476PubMedCrossRef Strosberg J, Gardner N, Kvols L (2009) Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 89:471–476PubMedCrossRef
9.
Zurück zum Zitat Ahmed A, Turner G, King B et al (2009) Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 16:885–894PubMedCrossRef Ahmed A, Turner G, King B et al (2009) Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 16:885–894PubMedCrossRef
10.
Zurück zum Zitat Jann H, Roll S, Couvelard A et al (2011) Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117:3332–3341PubMedCrossRef Jann H, Roll S, Couvelard A et al (2011) Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117:3332–3341PubMedCrossRef
11.
Zurück zum Zitat Cunningham JL, Grimelius L, Sundin A et al (2007) Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis. Acta Oncol 46:747–756PubMedCrossRef Cunningham JL, Grimelius L, Sundin A et al (2007) Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis. Acta Oncol 46:747–756PubMedCrossRef
12.
Zurück zum Zitat Akerstrom G (1989) Surgical treatment of carcinoids and endocrine pancreatic tumours. Acta Oncol 28:409–414PubMedCrossRef Akerstrom G (1989) Surgical treatment of carcinoids and endocrine pancreatic tumours. Acta Oncol 28:409–414PubMedCrossRef
13.
Zurück zum Zitat Akerstrom G, Makridis C, Johansson H (1991) Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 30:547–553PubMedCrossRef Akerstrom G, Makridis C, Johansson H (1991) Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 30:547–553PubMedCrossRef
14.
Zurück zum Zitat Makridis C, Rastad J, Oberg K et al (1996) Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J Surg 20:900–906 discussion 907PubMedCrossRef Makridis C, Rastad J, Oberg K et al (1996) Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J Surg 20:900–906 discussion 907PubMedCrossRef
15.
Zurück zum Zitat Moertel CG (1987) Karnofsky Memorial Lecture. An odyssey in the land of small tumors. J Clin Oncol 5:1502–1522PubMed Moertel CG (1987) Karnofsky Memorial Lecture. An odyssey in the land of small tumors. J Clin Oncol 5:1502–1522PubMed
16.
Zurück zum Zitat Ohrvall U, Eriksson B, Juhlin C et al (2000) Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg 24:1402–1408PubMedCrossRef Ohrvall U, Eriksson B, Juhlin C et al (2000) Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg 24:1402–1408PubMedCrossRef
17.
Zurück zum Zitat Eckhauser FE, Argenta LC, Strodel WE et al (1982) Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids. Surgery 90:720 Eckhauser FE, Argenta LC, Strodel WE et al (1982) Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids. Surgery 90:720
18.
Zurück zum Zitat Knowlessar O, Law D, Sleisinger MH (1959) Malabsorption syndrome associated with metastatic carcinoids. Am J Med 27:673–677CrossRef Knowlessar O, Law D, Sleisinger MH (1959) Malabsorption syndrome associated with metastatic carcinoids. Am J Med 27:673–677CrossRef
19.
Zurück zum Zitat Anthony P, Drury R (1970) Elastic vascular sclerosis of mesenteric blood vessels in argentaffin carcinoma. J Clin Pathol 23:110PubMedCrossRef Anthony P, Drury R (1970) Elastic vascular sclerosis of mesenteric blood vessels in argentaffin carcinoma. J Clin Pathol 23:110PubMedCrossRef
20.
Zurück zum Zitat Moertel CG, Sauer WG, Dockerty MB et al (1961) Life history of the carcinoid tumor of the small intestine. Cancer 14:901–912PubMedCrossRef Moertel CG, Sauer WG, Dockerty MB et al (1961) Life history of the carcinoid tumor of the small intestine. Cancer 14:901–912PubMedCrossRef
21.
Zurück zum Zitat Ahlman H, Wangberg B, Jansson S et al (1991) Management of disseminated midgut carcinoid tumours. Digestion 49:78–96PubMedCrossRef Ahlman H, Wangberg B, Jansson S et al (1991) Management of disseminated midgut carcinoid tumours. Digestion 49:78–96PubMedCrossRef
22.
Zurück zum Zitat Touzios JG, Kiely JM, Pitt SC et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241:776–783 discussion 783–775PubMedCrossRef Touzios JG, Kiely JM, Pitt SC et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241:776–783 discussion 783–775PubMedCrossRef
23.
Zurück zum Zitat Que FG, Sarmiento JM, Nagorney DM (2006) Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Adv Exp Med Biol 574:43–56PubMedCrossRef Que FG, Sarmiento JM, Nagorney DM (2006) Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Adv Exp Med Biol 574:43–56PubMedCrossRef
24.
Zurück zum Zitat Wangberg B, Westberg G, Tylen U et al (1996) Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 20:892–899 discussion 899PubMedCrossRef Wangberg B, Westberg G, Tylen U et al (1996) Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 20:892–899 discussion 899PubMedCrossRef
25.
Zurück zum Zitat Eriksson J, Stalberg P, Nilsson A et al (2008) Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 32:930–938PubMedCrossRef Eriksson J, Stalberg P, Nilsson A et al (2008) Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 32:930–938PubMedCrossRef
26.
Zurück zum Zitat Steinmuller T, Kianmanesh R, Falconi M et al (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87:47–62PubMedCrossRef Steinmuller T, Kianmanesh R, Falconi M et al (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87:47–62PubMedCrossRef
27.
Zurück zum Zitat Arnold R, Müller H, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 27:15s:(suppl; abstr 4508) Arnold R, Müller H, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 27:15s:(suppl; abstr 4508)
28.
Zurück zum Zitat Rindi G, Kloppel G, Couvelard A et al (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757–762PubMedCrossRef Rindi G, Kloppel G, Couvelard A et al (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757–762PubMedCrossRef
29.
Zurück zum Zitat Åkerström G, Hellman P, Hessman O (2009) Gastrointestinal carcinoids. In: Lennard T (ed) Endocrine surgery, 4th edn. Saunders Elsevier, London, pp 147–176 Åkerström G, Hellman P, Hessman O (2009) Gastrointestinal carcinoids. In: Lennard T (ed) Endocrine surgery, 4th edn. Saunders Elsevier, London, pp 147–176
30.
Zurück zum Zitat Oberg K (2003) Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 3:863–877PubMedCrossRef Oberg K (2003) Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 3:863–877PubMedCrossRef
31.
Zurück zum Zitat Janson ET, Ronnblom L, Ahlstrom H et al (1992) Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 3:635–638PubMed Janson ET, Ronnblom L, Ahlstrom H et al (1992) Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol 3:635–638PubMed
32.
Zurück zum Zitat Ederer F, Axtell LM, Cutler SJ (1961) The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 6:101–121PubMed Ederer F, Axtell LM, Cutler SJ (1961) The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 6:101–121PubMed
33.
34.
Zurück zum Zitat Dickman PW, Sloggett A, Hills M et al (2004) Regression models for relative survival. Stat Med 23:51–64PubMedCrossRef Dickman PW, Sloggett A, Hills M et al (2004) Regression models for relative survival. Stat Med 23:51–64PubMedCrossRef
35.
Zurück zum Zitat Modlin IM, Champaneria MC, Chan AK et al (2007) A three-decade analysis of 3, 911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol 102:1464–1473PubMedCrossRef Modlin IM, Champaneria MC, Chan AK et al (2007) A three-decade analysis of 3, 911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol 102:1464–1473PubMedCrossRef
36.
Zurück zum Zitat Talback M, Rosen M, Stenbeck M et al (2004) Cancer patient survival in Sweden at the beginning of the third millennium—predictions using period analysis. Cancer Causes Control 15:967–976PubMed Talback M, Rosen M, Stenbeck M et al (2004) Cancer patient survival in Sweden at the beginning of the third millennium—predictions using period analysis. Cancer Causes Control 15:967–976PubMed
37.
Zurück zum Zitat Tomassetti P, Campana D, Piscitelli L et al (2006) Endocrine tumors of the ileum: factors correlated with survival. Neuroendocrinology 83:380–386PubMedCrossRef Tomassetti P, Campana D, Piscitelli L et al (2006) Endocrine tumors of the ileum: factors correlated with survival. Neuroendocrinology 83:380–386PubMedCrossRef
38.
Zurück zum Zitat Burke AP, Thomas RM, Elsayed AM et al (1997) Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 79:1086–1093PubMedCrossRef Burke AP, Thomas RM, Elsayed AM et al (1997) Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 79:1086–1093PubMedCrossRef
39.
Zurück zum Zitat Makridis C, Ekbom A, Bring J et al (1997) Survival and daily physical activity in patients treated for advanced midgut carcinoid tumors. Surgery 122:1075–1082PubMedCrossRef Makridis C, Ekbom A, Bring J et al (1997) Survival and daily physical activity in patients treated for advanced midgut carcinoid tumors. Surgery 122:1075–1082PubMedCrossRef
40.
Zurück zum Zitat Elias D, Sideris L, Liberale G et al (2005) Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery 137:411–416PubMedCrossRef Elias D, Sideris L, Liberale G et al (2005) Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery 137:411–416PubMedCrossRef
41.
Zurück zum Zitat Vasseur B, Cadiot G, Zins M et al (1996) Peritoneal carcinomatosis in patients with digestive endocrine tumors. Cancer 78:1686–1692PubMedCrossRef Vasseur B, Cadiot G, Zins M et al (1996) Peritoneal carcinomatosis in patients with digestive endocrine tumors. Cancer 78:1686–1692PubMedCrossRef
42.
Zurück zum Zitat Lombard-Bohas C, Mitry E, O’Toole D, FFCD-ANGH-GERCOR (2009) Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology 89(2):217–222PubMedCrossRef Lombard-Bohas C, Mitry E, O’Toole D, FFCD-ANGH-GERCOR (2009) Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology 89(2):217–222PubMedCrossRef
43.
Zurück zum Zitat Hellman P, Lundstrom T, Ohrvall U et al (2002) Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 26:991–997PubMedCrossRef Hellman P, Lundstrom T, Ohrvall U et al (2002) Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 26:991–997PubMedCrossRef
44.
Zurück zum Zitat Soreide JA, van Heerden JA, Thompson GB et al (2000) Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients. World J Surg 24:1431–1436PubMedCrossRef Soreide JA, van Heerden JA, Thompson GB et al (2000) Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients. World J Surg 24:1431–1436PubMedCrossRef
45.
Zurück zum Zitat Ahlman H (1996) The role of surgery in patients with advanced midgut carcinoid tumours. Digestion 57(Suppl 1):86–87PubMedCrossRef Ahlman H (1996) The role of surgery in patients with advanced midgut carcinoid tumours. Digestion 57(Suppl 1):86–87PubMedCrossRef
46.
Zurück zum Zitat Oberg K (2000) Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 62(Suppl 1):92–97PubMed Oberg K (2000) Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 62(Suppl 1):92–97PubMed
47.
Zurück zum Zitat Faiss S, Pape UF, Bohmig M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689–2696PubMedCrossRef Faiss S, Pape UF, Bohmig M et al (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors—the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689–2696PubMedCrossRef
48.
Zurück zum Zitat Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130PubMedCrossRef Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130PubMedCrossRef
Metadaten
Titel
Long-Term Results of Surgery for Small Intestinal Neuroendocrine Tumors at a Tertiary Referral Center
verfasst von
Olov Norlén
Peter Stålberg
Kjell Öberg
John Eriksson
Jakob Hedberg
Ola Hessman
Eva Tiensuu Janson
Per Hellman
Göran Åkerström
Publikationsdatum
01.06.2012
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 6/2012
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-011-1296-z

Weitere Artikel der Ausgabe 6/2012

World Journal of Surgery 6/2012 Zur Ausgabe

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Wie sieht der OP der Zukunft aus?

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Recycling im OP – möglich, aber teuer

02.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.